PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33929994-5	2021	High degrees of apoptosis were observed among cell lines in which vandetanib suppressed ERK1/2 phosphorylation and upregulated the proapoptotic protein Bim, but this did not appear essential for vandetanib-induced cell death in all cell lines.	vandetanib	66-76	mitogen-activated protein kinase 3	Homo sapiens	88-94	
24526731-6	2014	Vandetanib significantly repressed tumorigenesis of MCF-7 xenografts (P < 0.001), which displayed decreased activation of ERK1/2 and AKT.	vandetanib	0-10	mitogen-activated protein kinase 3	Homo sapiens	125-131	
29517106-4	2018	Furthermore, vandetanib inhibited EGFR, AKT and ERK1/2 phosphorylation and downregulated cyclin D1 in ATC cells.	vandetanib	13-23	mitogen-activated protein kinase 3	Homo sapiens	48-54	
31299389-8	2019	In particular, we observed significant revascularisation of the microenvironment that is associated with upregulated ERK1/2 phosphorylation in regrown tumours post-vandetanib + PDT, thereby corroborating the importance of microenvironmental modification for the observed drug-PDT synergistic interaction.	vandetanib	164-174	mitogen-activated protein kinase 3	Homo sapiens	117-123	
20371720-9	2010	Additionally, ZD6474 inhibits activation of extracellular signal-regulated kinase 1/2 in both types of cells, and expression of a constitutively active phosphoinositide 3-kinases partially rescued ZD6474 inhibition in U87MG/EGFRvIII cells.	vandetanib	14-20	mitogen-activated protein kinase 3	Homo sapiens	44-85	
23578175-10	2013	Moreover, treatment with RET-inhibitors, including vandetanib, reduced cell viability, which was accompanied by the downregulation of the AKT and ERK1/2 signaling pathways.	vandetanib	51-61	mitogen-activated protein kinase 3	Homo sapiens	146-152	
16937523-5	2006	Treatment with gefitinib or ZD6474 also inhibited the expression of EGFR downstream signal molecules, p-Erk1/2 and p-Akt, although the magnitude of these effects varied between treatments and cell lines.	vandetanib	28-34	mitogen-activated protein kinase 3	Homo sapiens	104-110	
15367698-4	2004	EGF-mediated activation of EGFR and Erk-1/2 was decreased in tumor cells after ZD6474 treatment.	vandetanib	79-85	mitogen-activated protein kinase 3	Homo sapiens	36-43